Hospital guidelines for use of low-molecular-weight heparinsNUTESCU, Edith A; LEWIS, Richard K; FINLEY, Jamie M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1072-1081, issn 1060-0280, 10 p.Article

Increased Tumor Uptake of Chemotherapeutics and Improved Chemoresponse by Novel Non-anticoagulant Low Molecular Weight HeparinPHILLIPS, Patricia G; YALCIN, Murat; HUADONG CUI et al.Anticancer research. 2011, Vol 31, Num 2, pp 411-419, issn 0250-7005, 9 p.Article

Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinuxKOCH, Patrick.Contact dermatitis. 2003, Vol 49, Num 6, pp 276-280, issn 0105-1873, 5 p.Article

Molecular weight determines the frequency of delayed type hyper sensitivity reactions to heparin and synthetic oligosaccharidesLUDWIG, Ralf J; SCHINDEWOLF, Marc; ALBAN, Susanne et al.Thrombosis and haemostasis. 2005, Vol 94, Num 6, pp 1265-1269, issn 0340-6245, 5 p.Article

Low-molecular-weight heparin in pediatric patientsSUTOR, Anton Heinz; CHAN, Anthony K. C; MASSICOTTE, Patricia et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 31-39, issn 0094-6176, 9 p., SUP1Conference Paper

Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled HeparinFAREED, Jawed; WALENGA, Jeanine M; LINHARDT, Robert et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 119-127, issn 0094-6176, 9 p., SUP1Article

The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients: A randomised controlled trialTRABY, Ludwig; KAIDER, Alexandra; SCHMID, Rainer et al.Thrombosis and haemostasis. 2010, Vol 104, Num 1, pp 92-99, issn 0340-6245, 8 p.Article

Cancer and thrombosis: implications of published guidelines for clinical practiceKHORANA, A. A.Annals of oncology. 2009, Vol 20, Num 10, pp 1619-1630, issn 0923-7534, 12 p.Article

Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisationCHIA, Stanley; VAN COTT, Elizabeth M; RAFFEL, O. Christopher et al.Thrombosis and haemostasis. 2009, Vol 101, Num 3, pp 535-540, issn 0340-6245, 6 p.Article

Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis : Results of an in-vitro studyMAEGDEFESSEL, Lars; BUERKE, Michael; SCHUBERT, Sebastian et al.Thrombosis and haemostasis. 2008, Vol 100, Num 4, pp 693-698, issn 0340-6245, 6 p.Article

Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopeniaLOBO, Bob; FINCH, Christopher; HOWARD, Amanda et al.Thrombosis and haemostasis. 2008, Vol 99, Num 1, pp 208-214, issn 0340-6245, 7 p.Article

Removal of the anticoagulant activities of the low molecular weight heparin fractions and fragments with flavobacterial heparinaseYANG, V. C; BERNSTEIN, H; COONEY, C. L et al.Thrombosis research. 1986, Vol 44, Num 5, pp 599-610, issn 0049-3848Article

Heparin-induced thrombocytopenia and recent advances in its therapyHASSAN, Y; AWAISU, A; AZIZ, N. A et al.Journal of clinical pharmacy and therapeutics (Print). 2007, Vol 32, Num 6, pp 535-544, issn 0269-4727, 10 p.Article

New anticoagulants : towards the development of an ideal anticoagulantHAAS, S.VASA (Bern). 2009, Vol 38, Num 1, pp 13-29, issn 0301-1526, 17 p.Article

Extended perioperative thromboprophylaxis in patients with cancer : A systematic reviewAKL, Elie A; TERRENATO, Irene; BARBA, Maddalena et al.Thrombosis and haemostasis. 2008, Vol 100, Num 6, pp 1176-1180, issn 0340-6245, 5 p.Article

Hypersensitivity Reactions to Anticoagulant DrugsSCHERER, Kathrin; TSAKIRIS, Dimitrios A; BIRCHER, Andreas J et al.Current pharmaceutical design (Print). 2008, Vol 14, Num 27, pp 2863-2873, issn 1381-6128, 11 p.Article

Examining differences in weekly warfarin dose in patients with and without cancerGROGAN, Karen M; WONG, Candice; NUTESCU, Edith A et al.Therapeutic drug monitoring. 2007, Vol 29, Num 5, pp 638-643, issn 0163-4356, 6 p.Article

High platelet reactivity ― the challenge of prolonged anticoagulation therapy after ACS : High on-treatment platelet reactivityBROUWER, Marc A; JASPERS FOCKS, Jeroen; VERHEUGT, Freek W. A et al.Thrombosis and haemostasis. 2013, Vol 109, Num 5, pp 799-807, issn 0340-6245, 9 p.Article

Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolismJAVIER MARCHENA, Pablo; ANTONIO NIETO, José; GUIL, Maria et al.Thrombosis and haemostasis. 2012, Vol 107, Num 1, pp 37-43, issn 0340-6245, 7 p.Article

Cutaneous adverse drug reaction to heparins with hypereosinophilia and high IgE levelKLOS, Krzysztof; SPIEWAK, Radoslaw; KRUSZEWSKI, Jerzy et al.Contact dermatitis. 2011, Vol 64, Num 1, pp 61-62, issn 0105-1873, 2 p.Article

Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole bloodHOCHART, Helene; JENKINS, P. Vincent; PRESTON, Roger J. S et al.Thrombosis and haemostasis. 2008, Vol 99, Num 3, pp 570-575, issn 0340-6245, 6 p.Article

The Tainted Heparin Story: An UpdateGUERRINI, Marco; SHRIVER, Zachary; BISIO, Antonella et al.Thrombosis and haemostasis. 2009, Vol 102, Num 5, pp 907-911, issn 0340-6245, 5 p.Conference Paper

A marriage of enhancement: fibrinolysis and conjunctive therapy : Pharmacotherapy in cardiovascular diseases and vascular interventionsC.WELSH, Robert; ARMSTRONG, Paul W.Thrombosis and haemostasis. 2004, Vol 92, Num 6, pp 1194-1200, issn 0340-6245, 7 p.Article

Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibratorJESKE, W; AHMAD AHSAN; JAWED FAREED et al.Thrombosis research. 1993, Vol 70, Num 1, pp 39-50, issn 0049-3848Article

MINIMAL HEPARIN COFACTOR ACTIVITY IN DISSEMINATED INTRAVASCULAR COAGULATION AND CIRRHOSIS.BRAUNSTEIN KM; EURENIUS K.1976; AMER. J. CLIN. PATHOL.; U.S.A.; DA. 1976; VOL. 66; NO 3; PP. 488-494; BIBL. 21 REF.Article